Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants

Overview

The purpose of this study is to assess the way the body absorbs, distributes, breaks down and eliminates radioactive BMS-986856 in healthy males.

Full Title of Study: “Pharmacokinetics and Metabolism of a Single Dose of [14C] BMS-986256 in Healthy Male Participants”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 6, 2020

Detailed Description

Recruitment temporarily on hold due to COVID-19.

Interventions

  • Drug: BMS-986256
    • Specified dose on specified days
  • Drug: Milk of magnesia
    • Specified dose on specified days

Arms, Groups and Cohorts

  • Experimental: BMS-986256

Clinical Trial Outcome Measures

Primary Measures

  • Maximum observed plasma concentration (Cmax) of [14C] BMS-986256
    • Time Frame: Up to 49 days
  • Time to attain maximum observed plasma concentration (Tmax) of [14C] BMS-986256
    • Time Frame: Up to 49 days
  • Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)) of [14C] BMS-986256
    • Time Frame: Up to 49 days

Secondary Measures

  • Incidence of Adverse Events (AEs)
    • Time Frame: Up to 49 days
  • Incidence of Serious Adverse Events (SAEs)
    • Time Frame: Up to 49 days
  • Incidence of clinically significant changes in clinical laboratory results: Hematology tests
    • Time Frame: Up to 49 days
  • Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests
    • Time Frame: Up to 49 days
  • Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests
    • Time Frame: Up to 49 days
  • Incidence of clinically significant changes in vital signs: Blood pressure
    • Time Frame: Up to 49 days
  • Incidence of clinically significant changes in vital signs: Heart rate
    • Time Frame: Up to 49 days
  • Incidence of clinically significant changes in vital signs: Respiratory rate
    • Time Frame: Up to 49 days
  • Incidence of clinically significant changes in vital signs: Body temperature
    • Time Frame: Up to 49 days
  • Incidence of clinically significant changes in electrocardiogram (ECG) parameters
    • Time Frame: Up to 49 days
  • Incidence of clinically significant changes in physical examination findings
    • Time Frame: Up to 49 days

Participating in This Clinical Trial

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria

  • Healthy participants, as determined by no clinically significant deviations from normal in medical history, physical examination abnormalities that would compromise the ability to participate, complete, and/or interpret the results of the study, 12-lead electrocardiograms (ECGs), vital signs, and clinical laboratory results.
  • Males must agree to follow specific methods of contraception, if applicable, while participating in the trial

Exclusion Criteria

  • Any significant acute or chronic medical condition that presents a potential risk to the participant and/or that may compromise the objectives of the study
  • History of any significant drug and/or food allergies

Other protocol-defined inclusion/exclusion criteria apply

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Bristol-Myers Squibb
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bristol-Myers Squibb, Study Director, Bristol-Myers Squibb

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.